Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 7/20 | 0.48 |
| ▸ | THRB | P10828 | 7/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528770 | 0.92 | THRA (0.46) | THRATHRBCHEK2DGAT1HPSE | |
| SCHEMBL4299146 | 0.88 | THRA (0.49) | THRATHRBCHEK2DGAT1PPARG | |
| SCHEMBL3978262 | 0.85 | HDAC6 (0.48) | THRATHRBCHEK2DGAT1PPARG | |
| SCHEMBL3977650 | 0.85 | CHEK2 (0.44) | THRATHRBCHEK2DGAT1PPARG | |
| SCHEMBL3982935 | 0.84 | THRA (0.54) | THRATHRB | |
| SCHEMBL3980705 | 0.84 | HDAC6 (0.45) | THRATHRBCHEK2DGAT1PPARG | |
| SCHEMBL3978764 | 0.81 | CHEK2 (0.43) | THRATHRBCHEK2DGAT1PPARG | |
| SCHEMBL4302551 | 0.81 | CHEK2 (0.46) | THRATHRBCHEK2 | |
| SCHEMBL4300893 | 0.81 | CHEK2 (0.46) | THRATHRBCHEK2 | |
| SCHEMBL4299282 | 0.79 | THRA (0.44) | THRATHRBCHEK2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | claimed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | TSHR, TRHR, THRA | THRA 3/4885THRB 5/4885CHEK2 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.